Finalist
MS One to One™ patient support programme & healthcare professional e-platform (Aubagio®/Lemtrada®)
with support from Atlantis Healthcare
Summary of work
Multiple Sclerosis (MS) is a complex, chronic, disabling disease which affects about 2.5 million people worldwide.Twice as many women as men are affected, and are usually first diagnosed between the ages of 20 and 40, at a critical stage in adult life with often considerable family and work responsibilities.
Genzyme’s ‘MS One to One’ programme was created to ensure prescribers and patients with MS (PwMS) are fully apprised of appropriate use of Genzyme’s newly launched MS drugs. To achieve success, an education and support programme that adds value to stakeholders involved in the care of people with MS and improves the experience for MS patients on Genzyme MS treatments was created and rolled out across the EMEA region (Europe, Middle East & Africa).
‘MS One to One’ was created to provide a central point of information for HCPs and patients offering a broad range of multichannel communications, based on a proven behavioural approach, grounded in clinical evidence that supports personalised support and Risk Management Plan (RMP) requirements.
As of July 2015, ‘MS One to One‘ had been rolled-out and launched in 14 countries with over 7 more to follow.
Judges’ comments
The One to One™ programme was a multichannel approach with strong outcomes. It showed a sensible cascade of advocacy, a multichannel approach with nice learnings.
